mAbsolve is committed to improving the safety and effectiveness of therapeutic antibodies and Fc fusion proteins.
Forty years of Innovation
Now we have developed a new Fc variant which is more comprehensively silenced than previous antibodies. It is able to reduce unwanted inflammatory responses from the next generation of antibody-based drugs.
Building new Partnerships
We are building partnerships with Universities, Biotech and Pharma companies to licence this new technology and make it widely available. We hope that you will be next. Please contact us if you would like to hear more.